What is the CREAD 2?
A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer’s Disease (AD).
This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD. Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab or placebo every 4 weeks (q4w) for 100 weeks. The primary efficacy assessment will be performed at 105 weeks. The participants who do not enter open-label extension will enter for a long term follow-up period for up to 52 weeks after the last crenezumab dose (Week 153).
We’re looking for participants between 50 and 85 years old to join each study. Each participant should be able to nominate a ‘study partner’. The study partner may be a friend or family member who can provide support during the study and can attend some study visits with the participant. The study partner’s role is vital.
Study Website: https://www.creadstudy.com/index.aspx
For more information, click here.